Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS202
- Development stage
- Preclinical
- Lead developer
- Jiangsu Genscend Biopharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GS202 is a preclinical-stage bispecific monoclonal antibody being developed by Genscend Biopharmaceutical as a biosimilar/biobetter of amivantamab (Rybrevant). It is designed to target both the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (c-Met). By binding to these two receptors, GS202 is intended to inhibit downstream receptor signaling and promote immune-mediated tumor-cell killing, offering a potential therapeutic option for oncology indications, particularly EGFR-mutated non-small cell lung cancer (NSCLC) and other EGFR/c-Met-driven malignancies.
- Other names
- Amivantamab biosimilarAmivantamab-VMJM biosimilar
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on GS202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS202.